These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 25027109)

  • 21. Romosozumab increases bone mineral density in postmenopausal Japanese women with osteoporosis: A phase 2 study.
    Ishibashi H; Crittenden DB; Miyauchi A; Libanati C; Maddox J; Fan M; Chen L; Grauer A
    Bone; 2017 Oct; 103():209-215. PubMed ID: 28687496
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Oral daily ibandronate prevents bone loss in early postmenopausal women without osteoporosis.
    McClung MR; Wasnich RD; Recker R; Cauley JA; Chesnut CH; Ensrud KE; Burdeska A; Mills T;
    J Bone Miner Res; 2004 Jan; 19(1):11-8. PubMed ID: 14753731
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effect of soy isoflavone on bone mineral density in postmenopausal Taiwanese women with bone loss: a 2-year randomized double-blind placebo-controlled study.
    Tai TY; Tsai KS; Tu ST; Wu JS; Chang CI; Chen CL; Shaw NS; Peng HY; Wang SY; Wu CH
    Osteoporos Int; 2012 May; 23(5):1571-80. PubMed ID: 21901480
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis.
    Cosman F; Eriksen EF; Recknor C; Miller PD; Guañabens N; Kasperk C; Papanastasiou P; Readie A; Rao H; Gasser JA; Bucci-Rechtweg C; Boonen S
    J Bone Miner Res; 2011 Mar; 26(3):503-11. PubMed ID: 20814967
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of abaloparatide on bone mineral density and risk of fracture in postmenopausal women aged 80 years or older with osteoporosis.
    McClung MR; Harvey NC; Fitzpatrick LA; Miller PD; Hattersley G; Wang Y; Cosman F
    Menopause; 2018 Jul; 25(7):767-771. PubMed ID: 29462094
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of risedronate 150-mg once a month in the treatment of postmenopausal osteoporosis: 2-year data.
    McClung MR; Zanchetta JR; Racewicz A; Roux C; Benhamou CL; Man Z; Eusebio RA; Beary JF; Burgio DE; Matzkin E; Boonen S; Delmas P
    Osteoporos Int; 2013 Jan; 24(1):293-9. PubMed ID: 22752050
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of oral alendronate and intranasal salmon calcitonin on bone mass and biochemical markers of bone turnover in postmenopausal women with osteoporosis.
    Adami S; Passeri M; Ortolani S; Broggini M; Carratelli L; Caruso I; Gandolini G; Gnessi L; Laurenzi M; Lombardi A
    Bone; 1995 Oct; 17(4):383-90. PubMed ID: 8573412
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of postmenopausal osteoporosis with continuous daily oral alendronate in comparison with either placebo or intranasal salmon calcitonin.
    Adami S; Baroni MC; Broggini M; Carratelli L; Caruso I; Gnessi L; Laurenzi M; Lombardi A; Norbiato G; Ortolani S
    Osteoporos Int; 1993; 3 Suppl 3():S21-7. PubMed ID: 8298199
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial.
    Miller PD; Hattersley G; Riis BJ; Williams GC; Lau E; Russo LA; Alexandersen P; Zerbini CA; Hu MY; Harris AG; Fitzpatrick LA; Cosman F; Christiansen C;
    JAMA; 2016 Aug; 316(7):722-33. PubMed ID: 27533157
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Arzoxifene versus raloxifene: effect on bone and safety parameters in postmenopausal women with osteoporosis.
    Kendler DL; Palacios S; Cox DA; Stock J; Alam J; Dowsett SA; Zanchetta J
    Osteoporos Int; 2012 Mar; 23(3):1091-101. PubMed ID: 21374068
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of risedronate 5 mg/d on bone mineral density and bone turnover markers in late-postmenopausal women with osteopenia: a multinational, 24-month, randomized, double-blind, placebo-controlled, parallel-group, phase III trial.
    Välimäki MJ; Farrerons-Minguella J; Halse J; Kröger H; Maroni M; Mulder H; Muñoz-Torres M; Sääf M; Snorre Øfjord E
    Clin Ther; 2007 Sep; 29(9):1937-49. PubMed ID: 18035193
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bone mineral density gains with a second 12-month course of romosozumab therapy following placebo or denosumab.
    Kendler DL; Bone HG; Massari F; Gielen E; Palacios S; Maddox J; Yan C; Yue S; Dinavahi RV; Libanati C; Grauer A
    Osteoporos Int; 2019 Dec; 30(12):2437-2448. PubMed ID: 31628490
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Infusion of ibandronate once every 3 months effectively decreases bone resorption markers and increases bone mineral density in Chinese postmenopausal osteoporotic women: a 1-year study.
    Li M; Xing XP; Zhang ZL; Liu JL; Zhang ZL; Liu DG; Xia WB; Meng XW
    J Bone Miner Metab; 2010 May; 28(3):299-305. PubMed ID: 19855926
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Three-year denosumab treatment in postmenopausal Japanese women and men with osteoporosis: results from a 1-year open-label extension of the Denosumab Fracture Intervention Randomized Placebo Controlled Trial (DIRECT).
    Sugimoto T; Matsumoto T; Hosoi T; Miki T; Gorai I; Yoshikawa H; Tanaka Y; Tanaka S; Fukunaga M; Sone T; Nakano T; Ito M; Matsui S; Yoneda T; Takami H; Watanabe K; Osakabe T; Okubo N; Shiraki M; Nakamura T
    Osteoporos Int; 2015 Feb; 26(2):765-74. PubMed ID: 25403903
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study.
    Reginster JY; Adami S; Lakatos P; Greenwald M; Stepan JJ; Silverman SL; Christiansen C; Rowell L; Mairon N; Bonvoisin B; Drezner MK; Emkey R; Felsenberg D; Cooper C; Delmas PD; Miller PD
    Ann Rheum Dis; 2006 May; 65(5):654-61. PubMed ID: 16339289
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Suppressed bone turnover was associated with increased osteoporotic fracture risks in non-obese postmenopausal Chinese women with type 2 diabetes mellitus.
    Jiajue R; Jiang Y; Wang O; Li M; Xing X; Cui L; Yin J; Xu L; Xia W
    Osteoporos Int; 2014 Aug; 25(8):1999-2005. PubMed ID: 24760246
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy of risedronate administration in osteoporotic postmenopausal women affected by inflammatory bowel disease.
    Palomba S; Orio F; Manguso F; Falbo A; Russo T; Tolino A; Tauchmanovà L; Colao A; Doldo P; Mastrantonio P; Zullo F
    Osteoporos Int; 2005 Sep; 16(9):1141-9. PubMed ID: 15928801
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Skeletal effects of cyclic recombinant human growth hormone and salmon calcitonin in osteopenic postmenopausal women.
    Holloway L; Kohlmeier L; Kent K; Marcus R
    J Clin Endocrinol Metab; 1997 Apr; 82(4):1111-7. PubMed ID: 9100582
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of once-yearly zoledronic acid on the spine and hip as measured by quantitative computed tomography: results of the HORIZON Pivotal Fracture Trial.
    Eastell R; Lang T; Boonen S; Cummings S; Delmas PD; Cauley JA; Horowitz Z; Kerzberg E; Bianchi G; Kendler D; Leung P; Man Z; Mesenbrink P; Eriksen EF; Black DM;
    Osteoporos Int; 2010 Jul; 21(7):1277-85. PubMed ID: 19802508
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of discontinuing oral bisphosphonate treatments for postmenopausal osteoporosis on bone turnover markers and bone density.
    Naylor KE; Bradburn M; Paggiosi MA; Gossiel F; Peel NFA; McCloskey EV; Walsh JS; Eastell R
    Osteoporos Int; 2018 Jun; 29(6):1407-1417. PubMed ID: 29525970
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.